Long-term Anticoagulation in a Patient With Severe Hemophilia A

Report of a Clinical-biological Case: Long-term Anticoagulation in a Patient With Severe Hemophilia A

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07314983

Acronym

HAAC

Enrollment

Registered

2026-01-02

Start date

2025-09-22

Completion date

2026-01-31

Last updated

2026-01-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia A

Keywords

Hemophilia A, Severe Hemophilia A, factor VIII (FVIII) deficiency, Antithrombotic protection, Anticoagulant therapy

Brief summary

To date, and to our knowledge, no case of severe hemophilia A patients receiving long-term anticoagulation has been published. Severe hemophilia A is a hereditary bleeding disorder characterized by a factor VIII (FVIII) deficiency of \<1%. Anticoagulation remains a real challenge in these patients, given the precarious hemostatic balance between the bleeding risk associated with anticoagulation and the antithrombotic protection associated with factor VIII deficiency. The advent of new replacement therapies, characterized by FVIII molecules with a prolonged or very prolonged half-life, provides a high level of FVIII coverage (and therefore protection against the risk of bleeding) in patients receiving prophylaxis, thus facilitating the initiation of anticoagulation therapy.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patient (≥ 18 years) with severe hemophilia A * Absence of written objection in the subject's medical record to the reuse of their data for scientific research purposes.

Exclusion criteria

\- Subject having expressed objection to the reuse of their data for scientific research

Design outcomes

Primary

Measure	Time frame	Description
FVIII Level	Up to 15 months	Factor VIII (FVIII) is a clotting protein: it enables the blood to form a clot to stop bleeding. Its level indicates how well the blood clots, which is useful for diagnosing or monitoring hemophilia A before surgery. General values: * Normal: approximately 50 to 150% * Too low: risk of bleeding * Too high: may increase the risk of clots

Countries

France

Contacts

Primary ContactLaurent SATTLER, PharmD

laurent.sattler@chru-strasbourg.fr33 3 88 12 75 28

Outcome results